CHICAGO, IL—Administering the luteinizing hormone-releasing hormone (LHRH) analog goserelin with chemotherapy to women with early-stage, hormone receptor-negative breast cancer reduced premature ovarian failure by 70%, resulting in more pregnancies, compared with chemotherapy alone.
CHICAGO, IL— Weight loss associated with physical exercise and caloric restriction together appears to reduce breast cancer risk-modulating hormones among postmenopausal women more than dietary weight loss without exercise.
CHICAGO—Patients with non-small cell lung cancer (NSCLC) who acquire resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) had a higher overall response rate (ORR) to a novel selective EGFR inhibitor if they carried the T790M mutation.
CHICAGO—Cediranib plus olaparib “significantly extended” progression-free survival and objective response rate vs. olaparib alone in certain ovarian cancers.
At the 2014 ASCO Annual Meeting, Clifford A. Hudis, MD, FACP, became the first ASCO president to tweet his presidential address.
CHICAGO, IL—Combination ridaforolimus + MK-2206 AKT inhibitor therapy yielded modest early clinical efficacy results for patients with low-RAS advanced breast cancer and PTEN-deficient prostate cancer.
CHICAGO, IL—Fewer than 5% of adults with cancer enroll in clinical trials, despite such enrollment being critical to evaluate new therapies.
CHICAGO, IL—Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients’ quality of life.
CHICAGO, IL— Implementing the U.S. Preventive Services Task Force (USPSTF) recommendation for annual low-dose computed tomography (LDCT) lung cancer screening among high-risk smokers will more than double the proportion of early-stage lung cancer diagnoses among Medicare beneficiaries.
Obesity is associated with a 34% increase in mortality rates among premenopausal women with estrogen receptor (ER)-positive breast cancer.
Please login or register first to view this content.
